For every 4 to 5 radiation injury patients treated with HBOT, one achieves complete symptom resolution they would not have reached otherwise. That number-needed-to-treat figure, from a 2023 Cochrane review of 18 randomized trials (1,071 participants), makes HBOT one of the most effective interventions for late radiation tissue injury. About half of all cancer patients receive radiation, and the vascular damage it causes is progressive, often surfacing months or years after treatment ends.
Part of the BaricBoost HBOT Data series. Cite as: “HBOT for Radiation Injury: 2026 Cancer Survivor Outcomes & Clinical Data,” BaricBoost.com, July 2026.
HBOT for radiation tissue injury is one of the most established indications in hyperbaric medicine, classified among the 14 FDA-cleared indications and covered by Medicare and most private insurers. The evidence base spans a 2023 Cochrane review, multiple meta-analyses, and the largest radiation injury treatment registry ever assembled. This is one of several HBOT applications in cancer care.
Outcomes by Injury Type at a Glance
| Injury Type | Complete Resolution | Overall Improvement | Typical Sessions |
|---|---|---|---|
| Osteoradionecrosis (stage I-II) | 60 to 75% without surgery | Marx protocol cuts post-extraction ORN from ~30% to under 5% | 30 pre + 10 post, or 30 to 60 |
| Radiation cystitis | 55 to 65% (hematuria) | 84 to 90% | 30 to 40 |
| Radiation proctitis | 60 to 70% (bleeding stops) | 65 to 75% | 30 to 40 |
| Soft tissue radionecrosis | 60 to 75% healing | 85% at 12 months (breast LRTI series) | 40 to 60 |
| Neural tissue injury | No benefit | No benefit (Cochrane) | Not indicated |
Types of Radiation Injury Treated with HBOT
Osteoradionecrosis (ORN)
ORN occurs when radiation-damaged bone loses its blood supply and begins to die, most commonly in the mandible after head and neck cancer radiation. The 2023 Cochrane review found HBOT achieved mucosal coverage at RR 1.3 (95% CI 1.1 to 1.6, p=0.003, NNTB 5) and reduced ORN wound breakdown at RR 4.2 (95% CI 1.1 to 16.8, p=0.04, NNTB 4).1
- Resolution without surgery: 60 to 75% of stage I-II ORN
- Marx protocol: Pre- and post-operative HBOT around dental procedures in irradiated bone reduces ORN risk from roughly 30% to under 5%
- Typical protocol: 30 sessions pre-procedure plus 10 sessions post-procedure at 2.0 to 2.4 ATA
Radiation Cystitis
Radiation cystitis (bladder damage from pelvic radiation) causes hematuria, urgency, and frequency. Yang et al. (2024), a meta-analysis of 556 patients, reported 89.9% symptom improvement and 55% complete remission of hematuria (95% CI 51 to 59%).4 The largest systematic review, Villeirs et al. (2019) with 815 patients, found 87.3% overall response and 65.3% complete response.5
- Complete resolution of hematuria: 55 to 65%
- Overall symptom improvement: 84 to 90%
- Typical protocol: 30 to 40 sessions at 2.0 to 2.4 ATA
- Recurrence rate: about 14%; repeat HBOT is effective
Radiation Proctitis
Radiation damage to the rectum from pelvic radiation causes bleeding, pain, and bowel dysfunction. The Cochrane review found a relative risk of 1.72 (95% CI 1.0 to 2.9, p=0.04) for improvement or cure, with a number needed to treat of 5.1
- Symptom improvement: 65 to 75%
- Cessation of rectal bleeding: 60 to 70%
- Typical protocol: 30 to 40 sessions at 2.0 to 2.4 ATA
Soft Tissue Radionecrosis
Radiation damage to soft tissue can cause chronic wounds, fibrosis, and tissue breakdown. The Cochrane review found surgical flap survival improved markedly with HBOT (RR 8.7, 95% CI 2.7 to 27.5, p=0.0002, NNTB 4), one of the largest effect sizes in the entire evidence base.1
- Healing rate: 60 to 75% for soft tissue radionecrosis
- Breast LRTI: 85% improvement at 12 months in a case series of 67 patients8
- Typical protocol: 40 to 60 sessions at 2.0 ATA
How does HBOT reverse radiation damage?
HBOT reverses radiation damage by rebuilding the blood supply that radiation destroys. Radiation damages blood vessels progressively through endarteritis obliterans, the thickening and closure of small vessels. This creates a 3H tissue environment: hypoxic (low oxygen), hypocellular (few cells), and hypovascular (few blood vessels).
HBOT addresses each component:
- Hyperoxygenation: Immediately delivers oxygen to hypoxic tissue at 10 to 15 times normal levels
- Angiogenesis: Repeated sessions stimulate new blood vessel formation, creating a lasting vascular network
- Cellular repair: Improved oxygenation supports fibroblast activity, collagen synthesis, and tissue remodeling
The angiogenesis effect is the key to durability. A 30 to 60 session course produces vascular changes that persist and continue to support the treated tissue. Unlike treatments that address only symptoms, HBOT targets the underlying pathology that radiation created.
Cochrane Review Outcomes at a Glance
| Outcome | RR | NNT | Evidence Quality |
|---|---|---|---|
| ORN mucosal coverage | 1.3 (1.1-1.6) | 5 | Moderate |
| ORN wound breakdown prevention | 4.2 (1.1-16.8) | 4 | Moderate |
| Radiation proctitis improvement | 1.72 (1.0-2.9) | 5 | Low |
| Surgical flap survival | 8.7 (2.7-27.5) | 4 | Low |
| Dental extraction healing | 1.4 (1.1-1.7) | 4 | Low |
| ORN pain at 12 months | MD -10.72 | N/A | Moderate |
| Neural tissue injury | No benefit | N/A | N/A |
The number needed to treat is remarkably low. For every 4 to 5 patients treated with HBOT for radiation tissue injury, one additional patient achieves a significant clinical benefit compared with standard care alone (Cochrane review, Lin et al., 2023).1
What Does the HBOT Protocol Look Like?
| Condition | Sessions | Pressure | Schedule |
|---|---|---|---|
| ORN (Marx protocol) | 30 pre + 10 post-procedure | 2.4 ATA | Daily, 5 days/week |
| ORN (non-surgical) | 30 to 60 | 2.0 to 2.4 ATA | Daily, 5 days/week |
| Radiation cystitis | 30 to 40 | 2.0 to 2.4 ATA | Daily, 5 days/week |
| Radiation proctitis | 30 to 40 | 2.0 to 2.4 ATA | Daily, 5 days/week |
| Soft tissue radionecrosis | 40 to 60 | 2.0 ATA | Daily, 5 days/week |
How long do HBOT results last for radiation injury?
HBOT results for radiation injury are durable because the therapy rebuilds vasculature rather than masking symptoms. Five-year follow-up from the RICH-ART trial showed that 68.6% of patients who responded to HBOT for radiation-induced urinary symptoms maintained their improvement, with 12.8% requiring a repeat HBOT course.9 In breast cancer radiation injury, improvements in pain, fibrosis, and shoulder mobility persisted at 12 months after treatment.8 For radiation cystitis, the recurrence rate is about 14%, and repeat courses are often effective for those who do recur.
Five-year data now confirm what shorter studies suggested: HBOT-driven improvements in radiation injury symptoms are durable, with nearly 70% of responders holding their gains over the long term (RICH-ART trial, Oscarsson et al., 2025).9
Does Insurance Cover HBOT?
Radiation injury HBOT has among the most reliable insurance coverage of any indication:
- Medicare: Covered under NCD 20.29 for delayed radiation injury of soft tissue and bone
- Private insurance: Generally covered with prior authorization; many insurers have specific pathways for radiation injury referrals from oncologists
- Referral pathway: Typically a radiation oncologist or urologist refers to an HBOT center, with documentation of radiation history and tissue damage
Sources
- Lin Z, Bennett MH, Hawkins G, et al. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database Syst Rev, 2023;8:CD005005. 18 studies, 1,071 participants. DOI: 10.1002/14651858.CD005005.pub5. PMID: 37585677.
- Bennett MH, Feldmeier J, Smee R, Milross C. Hyperbaric oxygenation for tumour sensitisation to radiotherapy. Cochrane Database Syst Rev, 2018;4:CD005007. DOI: 10.1002/14651858.CD005007.pub4. PMID: 29637538.
- Niezgoda JA, Serena T, Carter MJ. Outcomes of Radiation Injuries Using Hyperbaric Oxygen Therapy. Adv Skin Wound Care, 2016;29(1):12-19. DOI: 10.1097/01.ASW.0000473679.29537.c0. PMID: 26650092.
- Yang TK, et al. Efficacy and Safety of Hyperbaric Oxygen Therapy for Radiation-Induced Hemorrhagic Cystitis. J Clin Med, 2024;13(16):4724. DOI: 10.3390/jcm13164724. PMID: 39200867.
- Villeirs L, et al. Hyperbaric oxygen therapy for radiation cystitis after pelvic radiotherapy. Int J Urol, 2019;26(12):1145-1156. DOI: 10.1111/iju.14130. PMID: 31617263.
- Cardinal J, et al. Scoping Review and Meta-analysis of Hyperbaric Oxygen Therapy for Radiation-Induced Hemorrhagic Cystitis. Curr Urol Rep, 2018;19(9):79. DOI: 10.1007/s11934-018-0790-3. PMID: 29654564.
- El Hadji S, et al. Hyperbaric oxygen therapy for late radiation tissue toxicity injury after head and neck cancer. Radiat Oncol, 2025;20:54. DOI: 10.1186/s13014-025-02680-1.
- Spruijt NE, van den Berg R. The effect of hyperbaric oxygen treatment on late radiation tissue injury after breast cancer. Diving Hyperb Med, 2020;50(3):206-213. DOI: 10.28920/dhm50.3.206-213. PMID: 32957121.
- Oscarsson N, et al. Radiation-induced cystitis treated with hyperbaric oxygen therapy (RICH-ART): long-term follow-up of a randomised controlled, phase 2-3 trial. eClinicalMedicine, 2025. 68.6% of responders sustained benefit at 5 years; 12.8% required a repeat course. DOI: 10.1016/j.eclinm.2025.103214. PMC12033922.
- Eckert KA, Fife CE, Carter MJ. Systematic Review of Hyperbaric Oxygen for Late Radiation Tissue Injury (Bowel, Bladder). Undersea Hyperb Med, 2025. DOI: 10.22462/754.
- Andren J, Bennett MH. An observational trial to establish the effect of hyperbaric oxygen on pelvic late radiation tissue injury. Diving Hyperb Med, 2020;50(3):250-255. DOI: 10.28920/dhm50.3.250-255. PMID: 32957127.
- Feldmeier JJ, Hampson NB. A systematic review of the literature reporting the application of hyperbaric oxygen in the prevention and treatment of delayed radiation injuries. Undersea Hyperb Med, 2002;29(1):4-30. PMID: 12507182.
Medical Disclaimer
The content on BaricBoost.com is for informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Author
Seph Fontane Pennock is the founder of BaricBoost.com and Regenerated.com, a clinic directory for regenerative medicine serving 10,000+ providers across the United States. He previously built and sold PositivePsychology.com, which grew to 19 million users and became the largest evidence-based positive psychology resource on the web. Seph brings direct experience as an HBOT patient, having completed protocols at clinics across three continents while navigating mold illness, systemic inflammation, and autoimmune conditions. His treatment journey includes hyperbaric oxygen therapy, peptide protocols, NAD+ therapy, and consultations with specialists from Dubai to Cape Town to Mexico. This combination of entrepreneurial track record and lived patient experience shapes everything published on BaricBoost.com. Every article is grounded in peer-reviewed research, informed by real clinical encounters, and written for patients making high-stakes treatment decisions. Seph's focus is on bringing transparency, scientific rigor, and practical guidance to the hyperbaric oxygen therapy space.
